프로티나
Financials
Valuation Metrics
프로티나's Market Cap is ₩4903B. Ranked #489 of 2,419 in KR market (top 20%), #188 of 1,638 on KOSDAQ (top 11%), #52 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 490.29B KRW | KR#489/2,419 Sec#52/231 |
| Revenue | 2.95B KRW | KR#2,371/2,419 Sec#207/231 |
| Net Income | -9.01B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 31.75B KRW | KR#2,327/2,419 Sec#221/231 |
| Net Assets | 28.37B KRW | KR#2,192/2,419 Sec#199/231 |
| Employees | 15 | KR#2,273/2,419 Sec#214/231 |
| Value | ||
| P/B | 17.28x | KR#2,392/2,419 Sec#220/231 |
| P/S | 166.15x | KR#2,396/2,419 Sec#215/231 |
| FCF Yield | -1.87% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -31.76% | KR#2,196/2,419 Sec#178/231 |
| ROA | -28.38% | KR#2,308/2,419 Sec#198/231 |
| Op. Margin | -385.23% | KR#2,353/2,419 Sec#197/231 |
| Financial Health | ||
| Debt Ratio | 11.91% | KR#185/2,419 Sec#35/231 |
| Total Debt | 0 KRW | KR—/2,419 Sec—/231 |
| FCF | -9.16B KRW | KR#1,680/2,419 Sec#144/231 |
| Cash | 8.79B KRW | KR#1,762/2,419 Sec#156/231 |
| Current Ratio | 15.15x | KR#49/2,419 Sec#16/231 |
| Performance | ||
| 1Y Return | -4.33% | KR#1,404/2,419 Sec#106/231 |
| 1M Return | 48.40% | KR#69/2,419 Sec#7/231 |
| From 52W High | -63.24% | KR#2,021/2,419 Sec#170/231 |
| 1Y MDD | -85.81% | KR#2,370/2,419 Sec#224/231 |
| Trading | ||
| Volume | 282,441 shares | KR#408/2,419 Sec#51/231 |
| Trading Value | 12.93B KRW | KR#224/2,419 Sec#25/231 |
| Foreign Own. | 2.51% | KR#1,453/2,419 Sec#137/231 |
| Per Share | ||
| EPS | -812 KRW | KR—/2,419 Sec—/231 |
| BPS | 2,555 KRW | KR#1,952/2,419 Sec#154/231 |
Company Info
Proteina Co., Ltd. is dedicated to pioneering technology for characterizing protein-protein interactions (PPIs). Their innovative approach enables the direct visualization of specific proteins to confirm the real-time activation of cancer signaling pathways. This capability helps predict drug efficacy and, crucially, empowers medical professionals to select optimal inhibitors by identifying bypass pathways that contribute to drug resistance. The company further offers a distinct single-molecule protein interaction detection platform, designed for in-depth analysis of protein and PPI information. Founded in 2015, Proteina Co., Ltd. is headquartered in Seoul, South Korea.